Uses of a chemokine receptor able to bind to MCP-1,...

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C436S503000, C424S145100, C514S012200

Reexamination Certificate

active

07655425

ABSTRACT:
A chemokine receptor binds to MCP-1, MIP-1α and/or RANTES. It can be used in screening for agents which act as antagonists to MCP-1, MIP-1α and/or RANTES. Such agents may be useful in treating various disorders, including allergies, atheromas and diseases mediated by viruses. They may also be useful in preventing graft rejection and in protecting stem cells from potentially damaging effects of chemotherapy.

REFERENCES:
patent: 5011912 (1991-04-01), Hopp et al.
patent: 6150132 (2000-11-01), Wells et al.
patent: 6919432 (2005-07-01), Wells et al.
patent: 2002/0160015 (2002-10-01), Wells et al.
patent: 0805859 (2005-04-01), None
patent: WO 92/20372 (1992-11-01), None
patent: WO 94/07521 (1994-04-01), None
patent: WO 94/11504 (1994-05-01), None
patent: WO 94/21277 (1994-09-01), None
patent: WO 94/29348 (1994-12-01), None
Elliot Marshall, Science, Mar. 2006. vol. 311, pp. 1688-1689.
Conroy et al, Journal of Leukocyte Biology, 2003. vol. 74, pp. 558-563.
Charo and Ransohoffds, New England Journal of Medicine, 2006, vol. 354, No. 6, pp. 610-621.
Bischoff et al. “RANTES and related chemokines activate human basophil granulocytes through different G protein-coupled receptors” Eur. J. Immunol. 23:761-767 (1993).
Charo, et al. “Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails” Proc. Natl. Acad. Sci. USA 91:2752-2756 (1994).
Chvatchko et al. “A key role for CC chemokine receptor 4 in lipopolysaccharide-induced endotoxic shock” J. Exp Med. 191:1755-1763 (2000).
Gao et al. “Structure and functional expression of the human macrophage inflammatory protein 1α/RANTES receptor” J. Exp. Med. 177:1421-1427 (1993).
Gao et al. “Human cytomegalovirus open reading frame US28 encodes a functional β chemokine receptor” J. Bio Chem. 269:28539-28542 (1994).
George et al. “Current methods in sequence comparison and analysis” Macromolecular Sequencing and Synthesis Selected Methods and Applications, Alan Liss Inc., New York, pp. 127-149 (1988).
Graham et al. “Identification and Characterization of an Inhibitor of haemopoietic stem cell proliferation” Nature 344:442-444. (1990).
Kawasaki et al. “Intervention of thymus and activation-regulated chemokine attenuates the development of allergic airway inflammation and hyperresponsive in mice” J. Immunol. 166:2055-2062 (2001).
Libert et al. “Selective amplification and cloning of four new members of the G protein-coupled receptor family” Science 244:569-572 (1989).
Neote et al. “Molecular cloning, functional characteristics of a CC chemokine receptor” Cell 72:415-425 (1993).
Panina-Bordignon et al. “The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics” J. Clin. Invest. 107:1357-1364 (2001).
Yamagami et al. “cDNA cloning and functional expression of a human monocyte chemoattractant protein 1 receptor” Biochem. Biophy. Res. Comm. 202:1156-1162 (1994).
Power et al. “Molecular cloning and functional expression of a novel CC chemokine receptor cDNA from a huma basophilic cell line” J. Biol. Chem. 270:19495-19500 (1995).
Int'l Search Report for PCT/GB96/00143 May 10, 1996.
Hoogewerf et al. “Molecular cloning of murine CC CKR-4 and high affinity binding of chemokines to murine and human CC CKR-4” Biochem.Biophys. Res. Comm. 218:337-343 (1996).
Horuk et al. “Molecular properties of the chemokine receptor family” TiPS 15:159-165 (1994).
Imai et al. “Molecular cloning of a novel T cell-directed CC chemokine expressed in thymus by signal sequence trap using Epstein-Barr virus vector” J. Biol. Chem. 271:21514-21521 (1996).
Imai et al. “The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4” J. Biol. Chem. 272:15036-15042 (1997).
Imai et al. “Macrophage-derived chemokine is a functional ligand for the CC chemokine receptor 4” J. Biol. Chem. 273:1764-1768 (1998).
Jones et al. “Replacing the complementarity-determining regions in a human antibody with those from a mouse” Nature 321:522-525 (1986).
Kelvin et al. “Chemokines and serpentines: The molecular biology of chemokine receptors” J. Leukocyte Biol. 54:604-612 (1993).
Riechmann et al. “Reshaping human antibodies for therapy” Nature 332:323-327 (1988).
Reiss et al. “CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin” J. Exp. Med. 194:1541-1547 (2001).
Barnes “New drugs for asthma” Nature Rev. 3:831-844 (2004).
Blom et al. Characterization of a human basophil-like cell line (LAMA-84) Scand. J. Immunol. 44:54-61 (1996).
Dahinden et al. “Monocyte chemotactic protein 3 is a most effective basophil- and eosinophil-activating chemokine” J. Exp. Med. 179:751-756 (1994).
Hulme et al. “Strategy and tactics in receptor-binding studies” inReceptor-Ligand Interactions, Hulme (ed.), Oxford Univ. Press, Chapter 4, pp. 63-175 (1992).
Iellem et al. “Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4+CD25+regulatory T cells” J. Exp. Med. 194:847-853 (2001).
Juremalm et al. “Selective CCL5/RANTES-induced mast cell migration through interactions with chemokine receptors CCR1 and CCR4” Biochem. Biophys. Res. Comm. 297:480-485 (2002).
Rang et al. “How drugs act: General principles” in Pharmacology, 2ndEd., Churchill Livingstone, Chapter 1, pp. 3-23 (1991).
Elliott et al. “Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α” Arth. & Rheumat. 36:1681-1690 (1993).
Gear et al. “Adenosine diphosphate strongly potentiates the ability of the chemokines MDC, TARC, and SDF-1 to stimulate platelet function” Blood 97:937-945 (2001).
Hopkin “Can super-antibody drugs be tamed?” Nature 440:855-856 (2006).
Jopling et al. “The identification, characterization, and distribution of guinea pig CCR4 and epitope mapping of a blocking antibody” J. Biol. Chem. 277:6864-6873 (2002).
Kawano et al. “Synthesis and biological evaluation of 2,4-diaminoquinazoline derivatives and related compounds as novel CC chemokine receptor 4 (CCR4) antagonists” MEDI abstract 376 at the 234thACS National Meeting, Boston, MA (Jul. 25, 2007) three pages.
Niwa et al. “Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma” Cancer Res. 64:2127-2133 (2004).
Presta “Selection, design, and engineering of therapeutic antibodies” J. Allergy Clin. Immunol. 116:731-736 (2005).
Purandare et al. “Antagonists of CCR4 as Immunomodulatory Agents” Curr. Topics Medicinal Chem. 6:1335-1344 (2006).
Ravensberg et al. “The effect of a single inhaled dose of a VLA-4 antagonist on allergen-induced airway responses and airway inflammation in patients with asthma” Allergy 61:1097-1103 (2006).
Scrip “Kyowa's anti-allergy antibody shows first signs of efficacy” PJB Publications Ltd. (Jul. 26, 2007).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Uses of a chemokine receptor able to bind to MCP-1,... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Uses of a chemokine receptor able to bind to MCP-1,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Uses of a chemokine receptor able to bind to MCP-1,... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4197868

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.